Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

Tenofovir disoproxil fumarate is associated with renal and bone toxicity. In a single-arm, open-label study of 242 virologically suppressed, HIV-infected participants with creatinine clearance 30–69 mL/min who switched to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, participants had...

Descripción completa

Detalles Bibliográficos
Autores principales: Post, Frank A., Tebas, Pablo, Clarke, Amanda, Cotte, Laurent, Short, William R., Abram, Michael E., Jiang, Shuping, Cheng, Andrew, Das, Moupali, Fordyce, Marshall W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228610/
https://www.ncbi.nlm.nih.gov/pubmed/27673443
http://dx.doi.org/10.1097/QAI.0000000000001186
_version_ 1782493974826582016
author Post, Frank A.
Tebas, Pablo
Clarke, Amanda
Cotte, Laurent
Short, William R.
Abram, Michael E.
Jiang, Shuping
Cheng, Andrew
Das, Moupali
Fordyce, Marshall W.
author_facet Post, Frank A.
Tebas, Pablo
Clarke, Amanda
Cotte, Laurent
Short, William R.
Abram, Michael E.
Jiang, Shuping
Cheng, Andrew
Das, Moupali
Fordyce, Marshall W.
author_sort Post, Frank A.
collection PubMed
description Tenofovir disoproxil fumarate is associated with renal and bone toxicity. In a single-arm, open-label study of 242 virologically suppressed, HIV-infected participants with creatinine clearance 30–69 mL/min who switched to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, participants had stable creatinine clearance, significant and durable improvements in proteinuria, albuminuria, and tubular proteinuria (P < 0.001), and significant increases in hip and spine bone mineral density through 96 weeks (P < 0.001). Eighty-eight percent maintained HIV-1 RNA <50 c/mL at week 96. These longer-term results support the use of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected individuals with mild-moderately impaired renal function.
format Online
Article
Text
id pubmed-5228610
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher JAIDS Journal of Acquired Immune Deficiency Syndromes
record_format MEDLINE/PubMed
spelling pubmed-52286102017-01-25 Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study Post, Frank A. Tebas, Pablo Clarke, Amanda Cotte, Laurent Short, William R. Abram, Michael E. Jiang, Shuping Cheng, Andrew Das, Moupali Fordyce, Marshall W. J Acquir Immune Defic Syndr Clinical Science Tenofovir disoproxil fumarate is associated with renal and bone toxicity. In a single-arm, open-label study of 242 virologically suppressed, HIV-infected participants with creatinine clearance 30–69 mL/min who switched to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, participants had stable creatinine clearance, significant and durable improvements in proteinuria, albuminuria, and tubular proteinuria (P < 0.001), and significant increases in hip and spine bone mineral density through 96 weeks (P < 0.001). Eighty-eight percent maintained HIV-1 RNA <50 c/mL at week 96. These longer-term results support the use of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected individuals with mild-moderately impaired renal function. JAIDS Journal of Acquired Immune Deficiency Syndromes 2017-02-01 2017-01-12 /pmc/articles/PMC5228610/ /pubmed/27673443 http://dx.doi.org/10.1097/QAI.0000000000001186 Text en Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Clinical Science
Post, Frank A.
Tebas, Pablo
Clarke, Amanda
Cotte, Laurent
Short, William R.
Abram, Michael E.
Jiang, Shuping
Cheng, Andrew
Das, Moupali
Fordyce, Marshall W.
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
title Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
title_full Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
title_fullStr Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
title_full_unstemmed Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
title_short Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
title_sort brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in hiv-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228610/
https://www.ncbi.nlm.nih.gov/pubmed/27673443
http://dx.doi.org/10.1097/QAI.0000000000001186
work_keys_str_mv AT postfranka briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study
AT tebaspablo briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study
AT clarkeamanda briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study
AT cottelaurent briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study
AT shortwilliamr briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study
AT abrammichaele briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study
AT jiangshuping briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study
AT chengandrew briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study
AT dasmoupali briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study
AT fordycemarshallw briefreportswitchingtotenofoviralafenamidecoformulatedwithelvitegravircobicistatandemtricitabineinhivinfectedadultswithrenalimpairment96weekresultsfromasinglearmmulticenteropenlabelphase3study

Ejemplares similares